Erin O'Brien

What is new in research on cannabis?

From dopamine detoxification for problem gaming to connections between bacteria and anxiety and depression, here are highlights from the week in Psychiatric Times.

What is new in research on bipolar disorder?

The results suggest that the bacterium Lactobacillus may aid in the management of stress and in the prevention of these disorders.

The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of November.

The FDA’s decision is set for September 2024.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

What is new in research on anxiety symptoms and disorders?

Psychiatric Times revisits some meaningful reflections on Thanksgiving, family traditions, and the value of gratitude and thankfulness.

From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

What is new in research on psychedelics?

From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.

What is new in research on dementia?

These results were instrumental in securing the FDA approval of the drug for the treatment of schizophrenia in adults in April 2023.

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.

What is new in research on SUDs?

Happy Halloween! To celebrate, Psychiatric Times® is looking back at our Scariest in Psychiatry series, which highlights clinicians’ most frightening, worrisome, and concerning issues in psychiatry.

The trial’s results showed statistically significant reductions in all major symptom domains and secondary endpoints.

The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.

From deep brain stimulation for treatment-resistant schizophrenia to a look at the potential trajectory of artificial intelligence in psychiatry and medicine, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of October.

What is new in research on TMS?

“Epidemiological surveys have shown that gender gaps and alcohol consumption and alcohol-related harms are narrowing for women and men—such that alcohol is growing women’s health issue.”

An expert addresses some common concerns about the drug and some effective ways clinicians can initiate the treatment at the 2023 Annual Psychiatric Times™ World CME Conference.

From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.

What is new in research on schizophrenia?

An expert discusses motivational interviewing at the 2023 Annual Psychiatric Times™ World CME Conference.

The NCE’s developer has announced that it is now initiating phase 3 studies.

This study is the first to assess the efficacy of this drug combination in a real-world setting.